Skip to main content

INVESTIGACION DE LA PATOGENESIS DE LA ENFERMEDAD DE PARKINSON MEDIANTE EL USO DE CELULAS MADRE HUMANAS

BFU2013-49157-P

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D (Excelencia / Generación de Conocimiento)
Call year 2013
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Whole-genome DNA hyper-methylation in iPSC-derived dopaminergic neurons from Parkinson's disease patients

  • Fernández-Santiago, Ruben
  • Merkel, Angelika
  • Castellano, Giancarlo
  • Heath, Simon
  • Raya Chamorro, Ángel
  • Tolosa, Eduard
  • Martí, Maria José
  • Consiglio, Antonella
  • Ezquerra, Mario
Background: Parkinson’s disease (PD) is characterized by the loss of midbrain dopaminergic neurons (DAn). Previously, we described the presence of DNA hyper- and hypo-methylation alterations in induced pluripotent stem cells (iPSC)-derived DAn from PD patients using the Illumina 450K array which prominently covers gene regulatory regions. Methods: To expand and contextualize previous findings, we performed the first whole-genome DNA bisulfite sequencing (WGBS) using iPSC-derived DAn from representative PD subjects: one sporadic PD (sPD) patient, one monogenic LRRK2-associated PD patient (L2PD), and one control. Results: At the whole-genome level, we detected global DNA hyper-methylation in the PD which was similarly spread across the genome in both sPD and L2PD and mostly affected intergenic regions. Conclusion: This study implements previous epigenetic knowledge in PD at a whole genome level providing the first comprehensive and unbiased CpG DNA methylation data using iPSC-derived DAn from PD patients. Our results indicate that DAn from monogenic or sporadic PD exhibit global DNA hyper-methylation changes. Findings from this exploratory study are to be validated in further studies analyzing other PD cell models and patient tissues., This work was supported by the Fondo de Investigaciones Sanitarias of the Instituto de Salud Carlos III (ISCIII) to M.E. (grant # PI14/00426), the Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED) to the Movement Disorders Unit of the Neurology Service from the Hospital Clínic de Barcelona to E.T., M.-J.M., R.F.-S., and M.E. (grant # PRI-16-2017). R.F.S. was supported by a Jóvenes Investigadores grant (#SAF2015-73508-JIN) through the Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad (Plan Estatal de I+D+I 2013–2016) of the Spanish Ministry of Economy and Competitiveness (MINECO), and the Agencia Estatal de Investigación (AEI), which is cofunded by FEDER (AEI/FEDER/UE). Other funding included the grants BFU2013-49157-P, BFU2016-80870-P, and the European Research Council (ERC) 2012-StG (311736- PD-HUMMODEL) to A.C; ISCIII/FEDER (RD16/0011/0024) and Generalitat de Catalunya (iPS4BioMed SGR 2017–2019) to A.R.; and ISCIII/FEDER (PIE14/00061) to A.R.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Whole-genome DNA hyper-methylation in iPSC-derived dopaminergic neurons from Parkinson's disease patients

  • Fernández-Santiago, Ruben
  • Merkel, Angelika
  • Castellano, Giancarlo
  • Heath, Simon
  • Raya Chamorro, Ángel
  • Tolosa, Eduard
  • Martí, Maria José
  • Consiglio, Antonella
  • Ezquerra, Mario
Background: Parkinson’s disease (PD) is characterized by the loss of midbrain dopaminergic neurons (DAn). Previously, we described the presence of DNA hyper- and hypo-methylation alterations in induced pluripotent stem cells (iPSC)-derived DAn from PD patients using the Illumina 450K array which prominently covers gene regulatory regions. Methods: To expand and contextualize previous findings, we performed the first whole-genome DNA bisulfite sequencing (WGBS) using iPSC-derived DAn from representative PD subjects: one sporadic PD (sPD) patient, one monogenic LRRK2-associated PD patient (L2PD), and one control. Results: At the whole-genome level, we detected global DNA hyper-methylation in the PD which was similarly spread across the genome in both sPD and L2PD and mostly affected intergenic regions. Conclusion: This study implements previous epigenetic knowledge in PD at a whole genome level providing the first comprehensive and unbiased CpG DNA methylation data using iPSC-derived DAn from PD patients. Our results indicate that DAn from monogenic or sporadic PD exhibit global DNA hyper-methylation changes. Findings from this exploratory study are to be validated in further studies analyzing other PD cell models and patient tissues., This work was supported by the Fondo de Investigaciones Sanitarias of the Instituto de Salud Carlos III (ISCIII) to M.E. (grant # PI14/00426), the Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED) to the Movement Disorders Unit of the Neurology Service from the Hospital Clínic de Barcelona to E.T., M.-J.M., R.F.-S., and M.E. (grant # PRI-16-2017). R.F.S. was supported by a Jóvenes Investigadores grant (#SAF2015-73508-JIN) through the Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad (Plan Estatal de I+D+I 2013–2016) of the Spanish Ministry of Economy and Competitiveness (MINECO), and the Agencia Estatal de Investigación (AEI), which is cofunded by FEDER (AEI/FEDER/UE). Other funding included the grants BFU2013-49157-P, BFU2016-80870-P, and the European Research Council (ERC) 2012-StG (311736- PD-HUMMODEL) to A.C; ISCIII/FEDER (RD16/0011/0024) and Generalitat de Catalunya (iPS4BioMed SGR 2017–2019) to A.R.; and ISCIII/FEDER (PIE14/00061) to A.R.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Aberrant epigenome in -derived dopaminergic neurons from Parkinson's disease patients

  • Fernández-Santiago, Rubén|||0000-0002-4582-0702
  • Carballo-Carbajal, Iria|||0000-0002-4403-8006
  • Castellano, Giancarlo|||0000-0002-5715-7733
  • Torrent, Roger
  • Richaud, Yvonne
  • Sánchez-Danés, Adriana
  • Vilarrasa-Blasi, Roser
  • Sánchez, Alex|||0000-0002-8673-7737
  • Mosquera, José Luis|||0000-0002-7852-4993
  • Soriano, Jordi
  • López-Barneo, José
  • Canals, Josep M.|||0000-0001-6829-7670
  • Alberch i Vié, Jordi|||0000-0002-8684-2721
  • Raya, Ángel|||0000-0003-2189-9775
  • Vila Bover, Miquel|||0000-0002-1352-989X
  • Consiglio, Antonella
  • Martín-Subero, José I.
  • Ezquerra, Mario|||0000-0003-3246-6641
  • Tolosa, Eduardo
The epigenomic landscape of Parkinson's disease () remains unknown. We performed a genomewide methylation and a transcriptome studies in induced pluripotent stem cell ()-derived dopaminergic neurons (n) generated by cell reprogramming of somatic skin cells from patients with monogenic 2-associated (L2) or sporadic (), and healthy subjects. We observed extensive methylation changes in n, and of expression, which were common in L2 and . No significant methylation differences were present in parental skin cells, undifferentiated s nor -derived neural cultures not-enriched-in-n. These findings suggest the presence of molecular defects in somatic cells which manifest only upon differentiation into the n cells targeted in . The methylation profile from n, but not from controls, resembled that of neural cultures not-enriched-in-n indicating a failure to fully acquire the epigenetic identity own to healthy n in . The -associated hypermethylation was prominent in gene regulatory regions such as enhancers and was related to the and/or protein downregulation of a network of transcription factors relevant to (1, 3C1, 4A, and 2). Using a patient-specific -based n model, our study provides the first evidence that epigenetic deregulation is associated with monogenic and sporadic PD.